A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Chinese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 20 May 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 19 Mar 2018 Planned initiation date changed from 26 Feb 2018 to 30 Mar 2018.
- 14 Nov 2017 New trial record